Wikipedia -WSS

Wikipedia

author：focus 2025-09-30 22:10:05 - browse：4

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： PhRMA lawsuit over Medicare drug price negotiation tossed

leisure time

WSS

How digital tools helped lower hypertension in marginalized patients

STAT Readout: Friday, Oct. 20 biotech updates

STAT Summit: The economic case for universal basic health care

Vaccine advisory panel ACIP left half staffed by HHS

Results on Novartis prostate cancer therapy could expand its use

Roche drug slashes death risk in early

focus

Wikipedia

explore

Affirmative action in medical school literally saved lives

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Continuity nursing helped my family in our darkest PICU moments

Study on Amgen’s bispecific immunotherapy produces positive data

Apple is now the first public company to be valued at $3 trillion

Robert F. Kennedy is pitching centrism on health, even on abortion

New air purifier tech could be key to improving indoor air quality

Smaller biotechs seek to piggyback on weight loss drug boom

At least 13 dead in Texas as scorching temps continue

A disappointing year of Humira biosimilars

focus

J&J lung cancer data amount to new salvo against AstraZeneca

BioAge raises $170M for combination therapy with Zepbound

STAT Readout: Friday, Oct. 20 biotech updates

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

STAT Readout Newsletter: Biotech news today

Readout LOUD podcast: How biotech is using artificial intelligence

leisure time

leisure time

explore

knowledge